Need adapted use of medication in the open dialogue approach for psychosis: a descriptive longitudinal cohort study

References

• Alanen, Y. O. (2009). Towards a more humanistic psychiatry: Development of need-adapted treatment of schizophrenia group psychosis. Psychosis, 1(2), 156–166. https://doi.org/10.1080/17522430902795667
   Web of Science ®Google Scholar
• Austin, P. C., & Stuart, E. A. (2015). Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statistics in Medicine, 34(28), 3661–3679. https://doi.org/10.1002/sim.6607
   PubMed Web of Science ®Google Scholar
• Bergström, T. (2020). Life after Integrated and Dialogical Treatment of First-Episode Psychosis. Long-Term Outcomes at the Group and Individual Level [ JYU Dissertations, 207].
   Google Scholar
• Bergström, T., Alakare, B., Aaltonen, J., Mäki, P., Köngäs-Saviaro, P., Taskila, J. J., & Seikkula, J. (2017). The long-term use of psychiatric services within the open dialogue treatment system after first-episode psychosis. Psychosis, 9(4), 310–321. https://doi.org/10.1080/17522439.2017.1344295
   Web of Science ®Google Scholar
• Bergström, T., Seikkula, J., Alakare, B., Kurtti, M., Köngäs-Saviaro, P., Löhönen, E., Miettunen, J., Mäkiollitervo, H., Taskila, J. J., Virta, K., & Valtanen, K. (2022). The 10-year treatment outcome of open dialogue-based psychiatric services for adolescents: A nationwide longitudinal register-based study. Early Intervention in Psychiatry. Advance online publication. https://doi.org/10.1111/eip.13286
   Google Scholar
• Bergström, T., Seikkula, J., Alakare, B., Mäki, P., Köngäs-Saviaro, P., Taskila, J. J., Tolvanen, A., & Aaltonen, J. (2018). The family-oriented open dialogue approach in the treatment of first-episode psychosis: Nineteen-year outcomes. Psychiatry Research, 270, 168–175. https://doi.org/10.1016/j.psychres.2018.09.039
   PubMed Web of Science ®Google Scholar
• Bergström, T., Taskila, J. J., Alakare, B., Köngäs-Saviaro, P., Miettunen, J., & Seikkula, J. (2020). Five-year cumulative exposure to antipsychotic medication after first-episode psychosis and its association with 19-year outcomes. Schizophrenia Bulletin Open, 1(1), sgaa050. https://doi.org/10.1093/schizbullopen/sgaa050
   Google Scholar
• Bola, J., Lehtinen, K., Cullberg, J., & Ciompi, L. (2009). Psychosocial treatment, antipsychotic postponement, and low-dose medication strategies in first-episode psychosis: A review of the literature. Psychosis, 1(1), 4–18. https://doi.org/10.1080/17522430802610008
   Web of Science ®Google Scholar
• Correll, C. U., Rubio, J. M., & Kane, J. M. (2018). What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry : Official Journal of the World Psychiatric Association (WPA), 17(2), 149–160. https://doi.org/10.1002/wps.20516
   PubMed Web of Science ®Google Scholar
• Danborg, P. B., & Gøtzsche, P. C. (2019). Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review. The International Journal of Risk & Safety in Medicine, 30(4), 193–201. https://doi.org/10.3233/JRS-195063
   PubMed Web of Science ®Google Scholar
• De Hert, M., Correll, C. U., & Cohen, D. (2010). Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophrenia Research, 117(1), 68–74. https://doi.org/10.1016/j.schres.2009.12.029
   PubMed Web of Science ®Google Scholar
• Francey, S. M., O’Donoghue, B., Nelson, B., Graham, J., Baldwin, L., Pan Yuen, H., Kerr, M. J., Ratheesh, A., Allott, K., Alvarez-Jimenez, M., Fornito, A., Harrigan, S., Thompson, A. D., Wood, S., Berk, M., & McGorry, P. D. (2020). Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: A randomized noninferiority clinical trial. Schizophrenia Bulletin Open, 1(1), sgaa015. https://doi.org/10.1093/schizbullopen/sgaa015
   Google Scholar
• Freeman, A. M., Tribe, R. H., Stott, J., & Pilling, S. (2019). Open dialogue: A review of the evidence. Psychiatric Services (Washington, DC), 70(1), 46–59. https://doi.org/10.1176/appi.ps.201800236
   PubMed Web of Science ®Google Scholar
• Harrow, M., Jobe, T. H., & Tong, L. (2021). Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders. Psychological Medicine, 1–11. Advance online publication. https://doi.org/10.1017/S0033291720004778
   Google Scholar
• Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021). A method for tapering antipsychotic treatment that may minimize the risk of relapse. Schizophrenia Bulletin, 47(4), 1116–1129. https://doi.org/10.1093/schbul/sbab017
   PubMed Web of Science ®Google Scholar
• Horowitz, M. A., Murray, R. M., & Taylor, D. (2021). Withdrawal-associated relapse is a potential source of bias. The Lancet: Psychiatry, 8(9), 747–748. https://doi.org/10.1016/S2215-0366(21)00250-9
   PubMed Web of Science ®Google Scholar
• Huhtaniska, S., Jääskeläinen, E., Hirvonen, N., Remes, J., Murray, G. K., Veijola, J., Isohanni, M., & Miettunen, J. (2017). Long-term antipsychotic use and brain changes in schizophrenia - a systematic review and meta-analysis. Human Psychopharmacology, 32(2), 10.1002/hup.2574. https://doi.org/10.1002/hup.2574
   PubMed Web of Science ®Google Scholar
• Isohanni, M., Jääskeläinen, E., Miller, B. J., Hulkko, A., Tiihonen, J., Möller, H.-J., Hartikainen, S., Huhtaniska, S., & Lieslehto, J. (2021). Medication management of antipsychotic treatment in schizophrenia – a narrative review. Human Psychopharmacology: Clinical and Experimental, 36(2), e2765. https://doi.org/10.1002/hup.2765
   Web of Science ®Google Scholar
• Isohanni, M., Mäkikyrö, T., Moring, J., Räsänen, P., Hakko, H., Partanen, U., Koiranen, M., & Jones, P. (1997). A comparison of clinical and research DSM-III-R diagnoses of schizophrenia in a Finnish national birth cohort. Clinical and research diagnoses of schizophrenia. Social Psychiatry and Psychiatric Epidemiology, 32(5), 303–308. https://doi.org/10.1007/BF00789044
   PubMed Web of Science ®Google Scholar
• Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. The British Journal of Psychiatry : The Journal of Mental Science, 188(2), 122–127. https://doi.org/10.1192/bjp.188.2.122
   PubMedGoogle Scholar
• Kirkbride, J. B., Croudace, T., Brewin, J., Donoghue, K., Mason, P., Glazebrook, C., Medley, I., Harrison, G., Cooper, J. E., Doody, G. A., & Jones, P. B. (2009). Is the incidence of psychotic disorder in decline? Epidemiological evidence from two decades of research. International Journal of Epidemiology, 38(5), 1255–1264. https://doi.org/10.1093/ije/dyn168
   PubMed Web of Science ®Google Scholar
• Kiviniemi, M. (2014). Mortality, disability, psychiatric treatment and medication in first-onset schizophrenia in Finland: The register linkage study. Oulu: Universitatis Ouluensis D, 1267.
   Google Scholar
• Korver-Nieberg, N., Quee, P. J., Boos, H. B., & Simons, C. J. (2011). The validity of the DSM-IV diagnostic classification system of non-affective psychoses. Australian & New Zealand Journal of Psychiatry, 45(12), 1061–1068. https://doi.org/10.3109/00048674.2011.620562
   PubMed Web of Science ®Google Scholar
• Lader, M., & File, S. (1987). The biological basis of benzodiazepine dependence. Psychological Medicine, 17(3), 539–547. https://doi.org/10.1017/s0033291700025794
   PubMed Web of Science ®Google Scholar
• Lehtinen, V., Aaltonen, J., Koffert, T., Räkköläinen, V., & Syvälahti, E. (2000). Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed? European Psychiatry : The Journal of the Association of European Psychiatrists, 15(5), 312–320. https://doi.org/10.1016/s0924-9338(00)00400-4
   PubMed Web of Science ®Google Scholar
• Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., Kissling, W., Stapf, M. P., Lässig, B., Salanti, G., & Davis, J. M. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet (London, England), 382(9896), 951–962. https://doi.org/10.1016/S0140-6736(13)60733-3
   PubMed Web of Science ®Google Scholar
• Moilanen, J. M., Haapea, M., Jääskeläinen, E., Veijola, J. M., Isohanni, M. K., Koponen, H. J., & Miettunen, J. (2016). Long-term antipsychotic use and its association with outcomes in schizophrenia - the Northern Finland birth cohort 1966. European Psychiatry : The Journal of the Association of European Psychiatrists, 36, 7–14. https://doi.org/10.1016/j.eurpsy.2016.03.002
   PubMed Web of Science ®Google Scholar
• Moncrieff, J., & Steingard, S. (2019). A critical analysis of recent data on the long-term outcome of antipsychotic treatment. Psychological Medicine, 49(5), 750–753. https://doi.org/10.1017/S0033291718003811
   PubMed Web of Science ®Google Scholar
• Morrison, A. P., Pyle, M., Maughan, D., Johns, L., Freeman, D., Broome, M. R., Husain, N., Fowler, D., Hudson, J., MacLennan, G., Norrie, J., Shiers, D., Hollis, C., James, A., Morrison, A. P., Pyle, M., Maughan, D., Johns, L., Freeman, D. … MAPS group. (2020). Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): A multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet: Psychiatry, 7(9), 788–800. https://doi.org/10.1016/S2215-0366(20)30248-0
   PubMed Web of Science ®Google Scholar
• Perälä, J. (2013). Epidemiology of psychotic disorders. National Institute for Health and Welfare and University of Helsinki, Department of Psychiatry, Research 97.
   Google Scholar
• Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M. (2017). Guidelines for the pharmacotherapy of schizophrenia in adults. Canadian Journal of Psychiatry: Revue Canadienne de Psychiatrie, 62(9), 604–616. https://doi.org/10.1177/0706743717720448
   PubMed Web of Science ®Google Scholar
• Seikkula, J., Aaltonen, J., Alakare, B., Haarakangas, K., Keränen, J., & Lehtinen, K. (2006). Five-year experience of first-episode nonaffective psychosis in open-dialogue approach: Treatment principles, follow-up outcomes, and two case studies. Psychotherapy Research, 16(2), 214–228. https://doi.org/10.1080/10503300500268490
   Web of Science ®Google Scholar
• Seikkula, J., Alakare, B., & Aaltonen, J. (2011). The comprehensive open-dialogue approach in Western Lapland: II. Long-term stability of acute psychosis outcomes in advanced community care. Psychosis, 3(3), 192–204. https://doi.org/10.1080/17522439.2011.595819
   Web of Science ®Google Scholar
• Seikkula, J., Alakare, B., Aaltonen, J., Holma, J., Rasinkangas, A., & Lehtinen, V. (2003). Open dialogue approach: Treatment principles and preliminary results of a two-year follow-up on first episode schizophrenia. Ethical Human Sciences & Serviceses, 5(3), 163–182.
   Google Scholar
• Sund, R. (2012). Quality of the Finnish hospital discharge register: A systematic review. Scandinavian Journal of Public Health, 40(6), 505–515. https://doi.org/10.1177/1403494812456637
   PubMed Web of Science ®Google Scholar
• Svedberg, B., Mesterton, A., & Cullberg, J. (2001). First-episode non-affective psychosis in a total urban population: A 5-year follow-up. Social Psychiatry and Psychiatric Epidemiology, 36(7), 332–337. https://doi.org/10.1007/s001270170037
   PubMed Web of Science ®Google Scholar
• Tiihonen, J., Mittendorfer-Rutz, E., Torniainen, M., Alexanderson, K., & Tanskanen, A. (2016). Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: An observational follow-up study. The American Journal of Psychiatry, 173(6), 600–606. https://doi.org/10.1176/appi.ajp.2015.15050618
   PubMed Web of Science ®Google Scholar
• Tiihonen, J., Tanskanen, A., & Taipale, H. (2018). 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. The American Journal of Psychiatry, 175(8), 765–773. https://doi.org/10.1176/appi.ajp.2018.17091001
   PubMed Web of Science ®Google Scholar
• Torniainen, M., Mittendorfer-Rutz, E., Tanskanen, A., Björkenstam, C., Suvisaari, J., Alexanderson, K., & Tiihonen, J. (2015). Antipsychotic treatment and mortality in schizophrenia. Schizophrenia Bulletin, 41(3), 656–663. https://doi.org/10.1093/schbul/sbu164
   PubMed Web of Science ®Google Scholar
• van Os, J., & Kapur, S. (2009). Schizophrenia. Lancet (London, England), 374(9690), 635–645. https://doi.org/10.1016/S0140-6736(09)60995-8
   PubMed Web of Science ®Google Scholar
• Whitaker, R. (2020). Viewpoint: Do antipsychotics protect against early death? A critical view. Psychological Medicine, 50(16), 2643–2652. https://doi.org/10.1017/S003329172000358X
   PubMed Web of Science ®Google Scholar
• Wunderink, L. (2019). Personalizing antipsychotic treatment: Evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders. Therapeutic Advances in Psychopharmacology, 9, 2045125319836566. https://doi.org/10.1177/2045125319836566
   Web of Science ®Google Scholar
• Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J. (2013). Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: Long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry, 70(9), 913–920. https://doi.org/10.1001/jamapsychiatry.2013.1
   PubMed Web of Science ®Google Scholar